文献速递重症综合管理与镇静镇痛

环泊酚用于ICU机械通气患者的早期镇静:2期和3期试验的汇总事后分析

Early sedation using ciprofol for intensive care unit patients requiring mechanical ventilation: a pooled post-hoc analysis of data from phase 2 and phase 3 trials.
PubMed 文献 · Ann Intensive Care · 2024-10-26
一句话结论汇总事后分析显示,环泊酚镇静30分钟内达到目标浅镇静者无低血压率高于丙泊酚(93.0% vs 81.0%,P=0.018)。

该汇总事后分析纳入2期和3期试验中预期需镇静6-24小时的ICU机械通气患者174例,按2:1随机分为环泊酚组116例和丙泊酚组58例,比较给药30分钟内达到目标浅镇静(RASS -2至+1)者的无低血压率。结果显示环泊酚组无低血压率显著高于丙泊酚组(93.0% vs 81.0%,P=0.018),男性及<65岁亚组更明显;多因素分析显示环泊酚治疗、较年轻年龄和较低基线BMI是无低血压率的独立有利预测因素。30分钟内达标且无低血压者短期预后更优,包括药物相关治疗中出现的不良事件发生率更低、拔管时间更短、剂量调整次数更少(均P<0.05)。

要点

  • 环泊酚组给药30分钟内达到目标浅镇静者的无低血压率为93.0%,丙泊酚组为81.0%(P=0.018)。
  • 男性及年龄<65岁亚组中,环泊酚的无低血压率优势更明显。
  • 多因素分析显示环泊酚治疗、较年轻年龄、较低基线BMI是无低血压率的独立有利预测因素。
  • 30分钟内达标且无低血压者药物相关治疗中出现的不良事件更少、拔管时间更短、剂量调整次数更少(均P<0.05)。
  • 两组均以RASS -2至+1为目标浅镇静,环泊酚负荷0.5 mg/kg、维持0.3 mg/kg/h,丙泊酚负荷1.0 mg/kg、维持1.5 mg/kg/h。

适用人群与场景

  • 预期需要镇静6-24小时的ICU机械通气患者,纳入2期和3期试验的合格人群。

诊断标准与关键阈值

  • 目标浅镇静定义为Richmond躁动-镇静评分(RASS)-2至+1。
  • 主要事后分析结局为给予环泊酚或丙泊酚30分钟达到目标镇静后的无低血压率。

处置流程与药物剂量

  • 环泊酚组:初始负荷剂量0.5 mg/kg,维持剂量0.3 mg/kg/h,按0.05-0.10 mg/kg/h速率上调或下调以达到目标浅镇静(RASS -2至+1)。
  • 丙泊酚组:初始负荷剂量1.0 mg/kg,维持剂量1.5 mg/kg/h,按0.25-0.50 mg/kg/h速率上调或下调以达到目标浅镇静(RASS -2至+1)。

研究设计与关键结果

  • 研究类型:2期和3期试验的汇总事后分析;样本量174例,环泊酚组116例、丙泊酚组58例,按2:1随机分组。
  • 主要结局:给药30分钟达到目标镇静者的无低血压率环泊酚组93.0% vs 丙泊酚组81.0%(P=0.018)。
  • 亚组:男性和年龄<65岁患者中环泊酚的无低血压率优势更明显。
  • 多因素分析:环泊酚治疗、较年轻年龄、较低基线BMI是无低血压率的独立有利预测因素。
  • 短期预后:30分钟达标且无低血压者药物相关治疗中出现的不良事件发生率更低、拔管时间更短、环泊酚或丙泊酚剂量调整次数更少(均P<0.05)。

证据类型、等级与局限

  • 证据类型:2期和3期随机对照试验的汇总事后分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于预期需要6-24小时镇静的ICU机械通气患者,作者认为使用环泊酚实现早期浅镇静可显著降低低血压发生率,并带来24小时内更有利的短期预后。

指南或共识出处

  • 2期试验(ClinicalTrials.gov,NCT04147416,注册日期2019年11月1日)和3期试验(ClinicalTrials.gov,NCT04620031,注册日期2020年11月6日)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Ciprofol was approved for use in intensive care unit (ICU) patients requiring sedation during mechanical ventilation in July 2022. A pooled post-hoc analysis of phase 2 and phase 3 trials was conducted primarily to explore hypotension-free outcome in ICU patients who required mechanical ventilation and achieved the target light sedation goal at an early stage after being sedated with ciprofol or propofol.

METHODS: All eligible ICU patients who were expected to require sedation for 6-24 h were randomly assigned in a 2:1 ratio to either a ciprofol or propofol group. Ciprofol or propofol was initially infused at loading doses of 0.5 or 1.0 mg/kg followed by maintenance doses of 0.3 or 1.5 mg/kg/h. Ciprofol or propofol dosages were adjusted up or down at rates of 0.05-0.10 mg/kg/h or 0.25-0.50 mg/kg/h, respectively, to achieve the target light sedation (a Richmond Agitation-Sedation Scale of -2 to + 1). The primary post-hoc outcome was the hypotension-free rate in patients who had achieved the target sedation goal after 30-min administration of ciprofol or propofol.

RESULTS: In total, 174 patients were enrolled for pooled post-hoc analysis, of whom 116 and 58 were assigned to the ciprofol and propofol groups, respectively. The hypotension-free rate was significantly higher in patients who achieved the target sedation goal after 30-min administration of ciprofol (93.0% vs. 81.0%, P = 0.018), and especially in the subgroups of males and patients aged < 65 years. Multivariable analysis revealed that ciprofol treatment, a younger age and lower baseline body mass index were independent favorable predictors for a higher hypotension-free rate in patients who achieved the target sedation goal after 30-min of drug administration. Moreover, hypotension-free patients who reached the target sedation level after 30 min had a more favorable short-term prognosis including a lower incidence of drug-related treatment-emergent adverse events, shorter time to extubation and fewer dose adjustments of ciprofol or propofol (all P < 0.05).

CONCLUSION: ICU patients undergoing mechanical ventilation and sedated with ciprofol had significantly lower rate of hypotension during the early phase of achieving light sedation during a 6-24 h period, leading to a more favorable short-term prognosis (within 24 h).

TRIAL REGISTRATION: Phase 2 trial (clinicaltrials.gov, NCT04147416. Registered November 1, 2019, https://classic.

CLINICALTRIALS: gov/ct2/show/NCT04147416 ) and phase 3 trial (clinicaltrials.gov, NCT04620031. Registered November 6, 2020, https://classic.

CLINICALTRIALS: gov/ct2/show/NCT04620031 ).

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Liu Y, Zuo L, Li X, et al. Early sedation using ciprofol for intensive care unit patients requiring mechanical ventilation: a pooled post-hoc analysis of data from phase 2 and phase 3 trials. Ann Intensive Care. 2024. PMID: 39455495. doi:10.1186/s13613-024-01390-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。